Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/3121
Назив: | Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals | Аутори: | Mirjana Bećarević | Кључне речи: | Antibodies against complement components;Antiphospholipid antibodies;Biomarkers;Biopharmaceuticals;Complement | Датум издавања: | 1-јул-2017 | Часопис: | Current Rheumatology Reports | Сажетак: | © 2017, Springer Science+Business Media New York. Purpose of Review: Laboratory criterion for the diagnosis of antiphospholipid syndrome (APS) is the presence of antiphospholipid antibodies (aPL Abs). Complement system has a role in mediating aPL Abs-induced thrombosis in animal models. The importance of antibodies against complement components (potential biomarkers of APS) and the importance of antibodies with beneficial anti-complement effects in APS (as biopharmaceuticals) are reviewed. Recent Findings: Antibodies against complement components described in APS patients, so far, are anti-C1q and anti-factor H Abs, although anti-factor B Abs and anti-C5a Abs were described in animal models of APS. Clinical studies in APS patients are limited to a small number of case reports. Summary: Studies that would confirm potential role of Abs against complement components (as potential biomarkers of APS) are lacking. Lack of randomized clinical trials (that would provide complete data for confirmation of beneficial effects of biopharmaceuticals in complement inhibition) in APS is alarming. | URI: | https://open.uns.ac.rs/handle/123456789/3121 | ISSN: | 15233774 | DOI: | 10.1007/s11926-017-0669-1 |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
6
проверено 10.05.2024.
Преглед/и станица
35
Протекла недеља
8
8
Протекли месец
6
6
проверено 10.05.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.